GlassScriptPhysician profile
Michael Sobieraj
NPI 1316441827
$1,072.48
in general payments reported to CMS, 2019-2025
9 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.19 · 2022: $167 · 2023: $185 · 2024: $209 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.60 |
| Education | $228.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $352.06 | 2022-2024 | Farxiga, Brilinta |
| Abbott Laboratories | $145.81 | 2025 | Ensite |
| Edwards Lifesciences Corporation | $125.63 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $107.94 | 2025 | |
| Bridgebio Pharma, INC. | $104.51 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.19 | 2021 | |
| Zimmer Biomet Holdings, INC. | $60.17 | 2025 | Avenir, Rosa |
| Smith+Nephew, INC. | $44.28 | 2023 | Tandem |
| Pfizer INC. | $38.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sobieraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.